Latest News for Adocia Stock (OTC:ADOCY)

Adocia is a clinical-stage biotechnology company. It specializes in the development of formulations of already approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The firm has developed Biochaperone, a proprietary technology platform to enhance the effectiveness of therapeutic proteins. The company's clinical pipeline includes Biochaperone Lispro, Biochaparone Combo, Biochaparone Glucagon, and others. Its pre-clinical pipeline includes BioChaperone LisPram, BioChaperone Glargine GLP-1, and BioChaperone Glucagon GLP1. Its patent portfolio mainly consists of chronic wound healing, insulin therapy, and monoclonal antibodies.

Adocia

RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) with a Sector Perform and raises the price target from $187 to $200.

News

Price Target

Analyst Ratings

RBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $200

Truist Securities analyst Jamie Cook maintains Oshkosh (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSK#NYSE">OSK</a>) with a Hold and raises the price target from $121 to $132.

Truist Securities Maintains Hold on Oshkosh, Raises Price Target to $132

WIIM

SNOW

Snowflake shares are trading higher after Microsoft reported strong growth in Azure.

MongoDB shares are trading higher after Microsoft reported strong growth in Azure.

Truist Securities analyst Scot Ciccarelli maintains O'Reilly Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>) with a Buy and lowers the price target from $1234 to $1212.

ORLY

Truist Securities Maintains Buy on O'Reilly Automotive, Lowers Price Target to $1212

Chevron CEO Says Not Planning To Make New Investments In California

Truist Securities analyst Robyn Karnauskas maintains Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) with a Buy and raises the price target from $142 to $143.

Truist Securities Maintains Buy on Merck & Co, Raises Price Target to $143

RBC Capital analyst Ken Herbert maintains Northrop Grumman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) with a Sector Perform and raises the price target from $450 to $475.

RBC Capital Maintains Sector Perform on Northrop Grumman, Raises Price Target to $475

Truist Securities analyst Neal Dingmann maintains Matador Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTDR#NYSE">MTDR</a>) with a Buy and raises the price target from $85 to $87.

MTDR

Truist Securities Maintains Buy on Matador Resources, Raises Price Target to $87

Macro Economic Events

Politics

Economics

General

President Biden, In Interview With Howard Stern Said, if I Am Elected Again, We Will Make Roe V. Wade The Law Of The Land Again; I Will Debate Trump, I Don't Know When

Truist Securities analyst Michael Swartz maintains MarineMax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HZO#NYSE">HZO</a>) with a Buy and lowers the price target from $40 to $35.

Truist Securities Maintains Buy on MarineMax, Lowers Price Target to $35

Applovin shares are trading higher. The stock may be up following strong earnings from Snap.

Truist Securities analyst Brandon King maintains Live Oak Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOB#NYSE">LOB</a>) with a Buy and lowers the price target from $47 to $38.

Truist Securities Maintains Buy on Live Oak Bancshares, Lowers Price Target to $38

Truist Securities analyst Ryan MacDonald maintains Laboratory Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Buy and lowers the price target from $270 to $255.

Laboratory Corporation Of America Holdings

Truist Securities Maintains Buy on Laboratory Corp, Lowers Price Target to $255

KNSL

Kinsale Capital Group shares are trading lower despite better-than-expected Q1 results.

Truist Securities analyst William Stein maintains Intel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) with a Hold and lowers the price target from $45 to $33.

INTC

Truist Securities Maintains Hold on Intel, Lowers Price Target to $33

RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Sector Perform and lowers the price target from $76 to $74.

GILD

RBC Capital Maintains Sector Perform on Gilead Sciences, Lowers Price Target to $74

Truist Securities analyst David Macdonald maintains Community Health Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) with a Hold and raises the price target from $3.25 to $3.75.

Truist Securities Maintains Hold on Community Health Sys, Raises Price Target to $3.75

Truist Securities analyst Barry Jonas maintains Churchill Downs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHDN#NASDAQ">CHDN</a>) with a Buy and raises the price target from $140 to $145.

CHDN

Truist Securities Maintains Buy on Churchill Downs, Raises Price Target to $145

RBC Capital analyst Maxim Matushansky maintains Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) with a Outperform and raises the price target from $47 to $53.

RBC Capital Maintains Outperform on Celestica, Raises Price Target to $53

Adocia SA reports 1H results

In a report released on July 26, Clémence Thiers from Kepler Capital maintained a Buy rating on Adocia SA (ADOIF – Research Report), with a price t...

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Latest News for Adocia Stock (OTC:ADOCY)

Wednesday, October 21, 2020